Drug intelligence / Profile preview

ibuprofen + methocarbamol

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

Ibuprofen + methocarbamol is an oral fixed-dose combination of two active pharmaceutical ingredients: ibuprofen and methocarbamol. **Ibuprofen** is a nonsteroidal anti-inflammatory drug (NSAID) that blocks cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis and thereby lowering pain, fever, and inflammation. **Methocarbamol** is a centrally acting muscle relaxant that acts mainly at the level of the central nervous system (spinal cord and brain), reducing muscle hyperactivity and spasms through CNS depression, though its precise mechanism remains incompletely defined. This combination provides symptomatic treatment of pain associated with muscle spasm, including back pain, muscle strains and sprains, and tense neck muscles. The combination is designed for short-term relief, aiming to combine analgesic, anti-inflammatory, and muscle relaxant effects[1][3][5][9].

Brand names
Robax PlatinumRobi-MIbugesic M
Other names
ibuprofen + methocarbamol
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on ibuprofen + methocarbamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibuprofen + methocarbamol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call